The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|September 1, 2021
Rheumatoid Arthritis Quiz: COVID-19 Booster Dose
Author(s)Ingrid Torjesen
Booster doses of the COVID-19 vaccine are recommended for many patients with rheumatoid arthritis. Test your knowledge on who is eligible for a booster and how it should be administered with this quiz.
Advertisement
The American College of Rheumatology recommends that patients with rheumatoid arthritis should receive a COVID-19 vaccine booster if they are taking most immunosuppressive or immunomodulatory therapies. However, the recommendations say that boosters are not needed for patients taking which one of the following treatments?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement